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ORIGINAL INVESTIGATION
T-cadherin deficiency increases vascular 
vulnerability in T2DM through impaired NO 
bioactivity
Han Wang1,2†, Ling Tao1*, Anastasia Ambrosio2†, Wenjun Yan1, Ross Summer3, Wayne Bond Lau2, Yajing Wang2 
and Xinliang Ma2*
Abstract 
Background: Endothelial dysfunction plays a critical role in the development of type 2 diabetes (T2DM). T-cadherin 
(T-cad) has gained recognition as a regulator of endothelial cell (EC) function. The present study examined whether 
T-cad deficiency increases vascular vulnerability in T2DM.
Methods: Vascular segments were isolated from WT or T-cad knockout mice. Endothelial function, total NO accumu-
lation, and the expression of T-cad related proteins were determined.
Results: Ach and acidified NaNO2 induced similar vasorelaxation in WT groups. T-cad KO mice exhibited nor-
mal response to acidified NaNO2, but manifested markedly reduced response to Ach. NO accumulation was also 
decreased in T-cad KO group. T-cad expression was reduced in WT mice fed 8 weeks of high fat diet (HFD). Further-
more, exacerbated reduction of vasorelaxation was observed in T-cad KO mice fed 8 weeks of HFD.
Conclusions: In the current study, we provide the first in vivo evidence that T-cadherin deficiency causes endothelial 
dysfunction in T2DM vascular segments, suggesting the involvement of T-cad deficiency in T2DM pathogenesis.
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Background
Type 2 diabetes mellitus (T2DM) affects approximately 
100 million people worldwide [1]. Diabetic vascular com-
plications are responsible for the majority of morbidity 
and mortality in the diabetic population. These compli-
cations can be arbitrarily divided into micro- and mac-
rovascular complications. Macrovascular complications 
are associated with accelerated atherosclerosis, resulting 
in premature ischemic heart disease, increased risk of 
cerebrovascular disease, and severe peripheral vascular 
disease [2].
Endothelial dysfunction is characterized by deficiency 
of nitric oxide (NO) production in response to normal 
secretion signals. A critical component of atherosclerosis 
development, endothelial dysfunction is a characteristic 
abnormality observed in diabetes [3–5]. The bioavailabil-
ity of NO, produced by endothelial NO synthase (eNOS), 
represents a key marker of vascular health. Down-regu-
lated NO may contribute to atherogenic predisposition. 
Many metabolic derangement factors cause endothelial 
dysfunction by affecting the balance of NO production 
during diabetes development [6–8]. Therefore, clarifica-
tion of the mechanisms responsible for endothelial dys-
function in diabetes, and identification of the therapeutic 
interventions that may improve endothelial function hold 
great potential in reducing cardiovascular complications 
and overall death in diabetic patients.
T-cadherin (T-cad) is a unique member of the cad-
herin family. Found on the cellular surface, it possesses 
no intracellular domain. T-cadherin content is maximal 
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in the aorta, carotid, iliac, and renal arteries, and in the 
heart. Known to regulate neuronal growth during embry-
ogenesis, T-cad has additionally gained recognition as a 
regulator of endothelial cell (EC) function [9–11].
In vivo expression of T-cad is increased in human 
atherosclerotic lesions and experimental restenosis. 
In  vitro expression of T-cad is upregulated in prolif-
erating endothelial and smooth muscle cells, as well 
as endothelial cells during oxidative and endoplasmic 
reticulum stress [11, 12]. Clinical evidence underlines 
the association between T-cad and hypoadiponectine-
mia, with increased risk of various metabolic diseases 
[13, 14]. Together, these observations strongly suggest 
the involvement of T-cad in diabetic vasculopathic state 
development. However, direct evidence that supported 
T-cadherin deficiency exists in diabetic endothelial dys-
function pathogenesis is currently lacking.
Therefore, the aims of the present study were: (1) to 
determine whether T-cad deficiency is involved in the 
development of T2DM, (2) to determine whether T-cad 
deficiency may cause endothelial dysfunction in descend-
ing aortic vascular segments (the most frequent loca-
tion of atherosclerosis development), (3) to determine 
whether endothelial dysfunction is exacerbated by T-cad 
deficiency in descending aortic vascular segments in 
T2DM, and (4) to elucidate the responsible underlying 
mechanisms.
Methods
Determination of vasorelaxation in aortic tissue
Adult male T-cad knockout mice (T-cad KO) or their 
wild type littermates (WT) were used in all study experi-
ments. All experiments were performed in adherence to 
the NIH Guidelines on the Use of Laboratory Animals, 
and approved by the Thomas Jefferson University Com-
mittee on Animal Care. After animals were anesthetized 
with 3% isoflurane, descending aortas were removed and 
placed into cold Krebs buffer solution [NaCl 118, KCl 
4.75, CaCl2·2H2O 2.54, KH2PO4 1.19, MgSO4·7H2O 1.19, 
NaHCO3 25, and glucose 10.0 (mM)] Aorta were care-
fully cut into 2–3 segments (each 2–3 mm length); sur-
rounding fat and tissue were debrided. Segments were 
suspended upon stainless steel hooks, and aerated (95% 
O2 and 5% CO2) in 37  °C 5  ml  K–H tissue baths. Aor-
tic rings were connected to FORT-10 force transducers 
(WPI, Sarasota, FL) for MacLab data acquisition. Seg-
ments were first stretched to generate 2.5 mN force, fol-
lowed by 0.5 mN increments every 15 min until achieving 
4 mN total force. As force was increased to 8mN, the 
Krebs buffer solution was replaced with a buffer with 
increased potassium content (HK solution) for vessel 
ring sustainability. Once 8 mN force was achieved, the 
tissue bath was replaced with normal Krebs buffer. Dur-
ing the period of force decrease from 8 to 4 mN, epineph-
rine (a potent vasoconstrictor) was added to the tissue 
bath in 2 concentrations (10−5 and 10−4 M) in sequence 
within 2  min of each other, to induce vasoconstriction. 
After ~5 min, the vasorelaxant acetylcholine (concentra-
tions of 10−6, 10−5, 10−4, 10−3 and 10−2 M) were added 
to the tissue bath in immediate succession. The percent 
relaxation from the peak of the epinephrine-induced 
contraction to the nadir point of acetylcholine-induced 
relaxation was recorded on MacLab.
Determination of NO accumulation from aortic segments
To determine total NO accumulation, isolated aortic seg-
ments were placed in culture medium and incubated in a 
cell culture incubator (5% CO2, 37 °C). After 8 h of incu-
bation, segments were subjected to homogenization. Pro-
tein concentrations were determined via BCA method 
(Pierce Chemical). Medium was transferred into the wells 
of 96-well plate, and incubated with nitrate reductase 
and cofactors for 20 min at 37 °C to reduce NO3 to NO2. 
Samples (50 μl) were then injected into a water-jacketed, 
oxygen-free purge vessel containing 5  ml of 20  mM 
potassium iodide in glacial acetic acid to reduce NO2 to 
NO. Resultant chemiluminescence from the reaction of 
NO and ozone was detected by a nitric oxide analyzer 
(SIEVERS NOA 280I; Sievers, Boulder, CO). Detector 
signals were collected and analyzed by a PC-based data 
recording and processing system. To determine the NO 
content of the culture medium, calculations of the slope 
of the regression analysis were performed. The amount of 
NOx released was expressed in nmol/mg protein.
Determination of NOx production from aortic segments
To detect endothelial NOx production, isolated aortic 
segments were placed in 6-well plates with 500  μl cul-
ture medium. Epinephrine (10−4  M) was added to each 
well. 3  min later, acetylcholine concentrations (10−6, 
10−5, 10−4, 10−3 and 10−2  M) were added in immediate 
succession. Resultant medium nitrite (NO2−) and nitrate 
(NO3−) levels were determined by chemiluminescence 
NO detector (Siever 280i NO Analyzer).
Quantitation of tissue nitrotyrosine content
Nitrotyrosine content, the accepted footprint of in  vivo 
peroxynitrite (ONOO−) formation, was determined by 
ELISA described in our previous publication [15]. In 
brief, aortic segments were homogenized in lysis buffer 
and centrifuged for 10 min at 12,000g at 4  °C. Superna-
tants were collected and protein concentrations were 
determined. Tissue samples from aortic segments, were 
applied to disposable sterile ELISA plates, and incubated 
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overnight with primary antibody against nitrotyros-
ine (05–233, Millipore, USA). After extensive wash and 
incubation with the peroxidase-conjugated secondary 
antibody, the peroxidase reaction product was generated 
using TMB solution. The optical density was measured at 
450 nm with a SpectraMax-Plus microplate spectropho-
tometer. The amount of nitrotyrosine content in tissue 
samples was calculated using standard curves generated 
from nitrated BSA containing known amounts of nitroty-
rosine, and expressed as pmol/mg protein.
Immunoblotting
Aortic tissue homogenate proteins were separated on 
SDS-PAGE gels, transferred to PVDF membranes, and 
Western blotted with monoclonal antibody against 
eNOS, Ser1177 phosphorylated eNOS (Becton–Dick-
inson, USA), and polyclonal antibody against Akt and 
Ser473 phosphorylated Akt (Cell Signaling Technology, 
USA). PVDF membranes were incubated with horserad-
ish peroxide-conjugated anti-rabbit or anti-mouse IgG 
antibodies (Cell Signaling Technology, USA) for 2 h. The 
blot was developed using Super-Signal Reagent (Pierce) 
and visualized with a Kodak Image Station 4000R. Blot 
densities were analyzed (Gelpro32 software).
Real‑time PCR
Total RNA was extracted from aortic segments via RNe-
asy Mini Kit (QIAGEN, USA). Expression analysis of 
the reported genes was performed by real-time PCR 
via commercial kit (4367659, AB) and the ABI 7500 
Sequence Detection System, using SYBR GREEN as a 
double-stranded DNA-specific dye. GAPDH served as 
endogenous control. Table 1 lists the primers for mRNA 
expression analysis by real-time PCR.
Statistical analysis
All values in the text, table, and figures are presented 
as mean  ±  SEM of n independent experiments. Data 
(except Western blot density) were subjected to t test 
(two groups) or ANOVA (three or more groups) followed 
by Bonferoni correction for post hoc t test. Western blot 
densities were analyzed by the Kruskal–Wallis test fol-
lowed by Dunn’s post test. Probabilities of 0.05 or less 
were considered to be statistically significant.
Results
T‑cad mRNA and protein expression decreased in WT mice 
fed 8 weeks HFD
We first determined T-cad expression during T2DM 
condition. In an established diet-induced T2DM model, 
we fed WT mice high fat diet for 8  weeks, and deter-
mined both the mRNA and protein levels of T-cadherin 
[16]. Both mRNA and protein levels of T-cadherin were 
reduced compared to control, suggesting T-cadherin 
deficiency occurs during type 2 diabetes (Fig. 1).
T‑cad deficiency induced endothelial dysfunction
We next performed a vascular ring experiment to directly 
address this relationship. In WT aortic rings, adminis-
tration of Ach (an endothelial-dependent NO donor) 
resulted in concentration-dependent vasorelaxation, with 
no significant difference compared to the effects elicited 
by acidified NaNO2 (an endothelial-independent NO 
donor). At maximal concentration (100  μM), Ach and 
acidified NaNO2 induced 79.7 and 85.9% vasorelaxa-
tion respectively, demonstrating preserved vascular ring 
endothelial function post-preparation protocols. How-
ever, aortic rings from T-cad KO mice exhibited markedly 
reduced vasorelaxation by Ach (endothelial-dependent 
stimulation) treatment compared to that induced by acid-
ified NaNO2 (endothelial-independent NO donor) treat-
ment. Furthermore, addition of 100 μM Ach resulted in 
only 54.5% relaxation (P < 0.01 vs. WT) in T-cad KO aor-
tic ring; 100 μM acidified NaNO2 induced 82.3% relaxa-
tion (P  >  0.05 vs. WT) (Fig.  2). Together, these results 
demonstrate T-cad deficiency resulted in severe endothe-
lial dysfunction in the tested aortic segments.
T‑cad deficiency‑induced endothelial dysfunction 
exacerbated in T2DM
The above experiments verified T-cad deficiency occurs 
in T2DM, and T-cad deficiency was associated with vas-
cular segment endothelial dysfunction. Next, we deter-
mined the state of endothelial function in T-cad KO 
animals under in-viro or in  vivo diabetic environment. 
We first utilized an in vitro model of diabetes, employing 
high glucose (HG, 25.5 mmol/l), high fat (HF, palmitate 
300 μmol/l) treatment. After incubating aortic rings from 
WT and T-cad KO mice in HGHF (2.5 h), vasorelaxation 
was impaired in both animal types. However, the reduc-
tion in concentration-dependent vasorelaxation was 
markedly increased in T-cad KO mice compared to WT. 
To better mimic in  vivo T2DM, we next fed WT mice 
and T-cad KO mice 8  weeks of HFD diet as previously 
described [17]. Again, ring vasorelaxation was reduced in 
both WT and T-cad KO mice. Vasorelaxation reduction 
was more pronounced in T-cad KO mice compared to 
WT mice (Fig. 3). Collectively, these results suggest that 
Table 1 Primers sequences for Real-time PCR analysis
Genes Primers
GAPDH-F (mouse) 5′-AGGTCGGTGTGAACGGATTTG-3′
GAPDH-R (mouse) 5′-TGTAGACCATGTAGTTGAGGTCA-3′
T-cad-F (mouse) 5′-CATCGAAGCTCAAGATATGG-3′
T-cad-R (mouse) 5′-GATTTCCATTGATGATGGTG-3′
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Fig. 1 T-cad mRNA and protein expression were reduced in WT mice fed 8 weeks HFD. T-cad expression as measured by Western blot and real time 
PCR a representative Western blots; b Western blot density analysis (n = 4); c Real time PCR analysis (n = 3).**P < 0.01 vs. WT
10-7 10-510-6 10-4
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Fig. 2 T-cad deficiency induced endothelial dysfunction. Concentration-dependent vasorelaxation of aortic vascular rings in response to a Ach, an 
endothelium-dependent vasodilator, and b acidified NaNO2, an endothelium-independent vasodilator. Top representative figures; Bottom analysis 
result. Each mouse aorta generated 2–3 rings, n = 8–12 rings/group. WT wild type litternates, T-cad KO T-cadherin knockout mice. *P < 0.05 vs. WT
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endothelial dysfunction caused by T-cad deficiency was 
exacerbated in the T2DM condition.
Total NO accumulation and NOX production significantly 
decreased in vascular segments from T‑cad KO animals
Next, total NO accumulation and NOx production were 
determined. Aortic segments were isolated from WT 
and T-cad KO animals, and incubated with cell culture 
medium. Culture media was collected after 8 h. Total NO 
accumulation in aortic segments from T-cad KO mice 
was significantly decreased compared to WT (Fig. 4). To 
measure direct NO release after Ach stimulation, total 
NOx production was determined. As expected, total NOx 
production was markedly decreased in T-cad KO mice 
compared to WT. Together, these results demonstrate 
that T-cad deficiency was associated with reduced NO 
production, which may be responsible in part for the 
observed state of endothelial dysfunction.
Phosphorylation of Akt, but not eNOS, was significantly 
reduced in T‑cad KO aortic tissue
To study the underlying mechanisms, we performed 
Western blot. Akt phosphorylation was significantly 
increased in T-cad KO mice compared to WT (Fig.  5), 
consistent with known current research. However, eNOS 
phosphorylation in T-cad KO mice was slightly increased 
(not to significant degree) compared to WT. These results 
suggest that reduction of NO bioavailability caused by 
T-cad deficiency may induce phosphorylation of the Akt-
eNOS pathways in compensatory manner, without sig-
nificant effect.
Akt inactivation increases caspase‑3 activity in HUVECs
To further investigate the contributive mechanisms 
of reduced NO bioactivity, we cultured and subjected 
human umbilical vein endothelial cells (HUVECs) to Akt 
inhibitor (A6730, Sigma, (10  μM) treatment for 24  h. 
Akt phosphorylation and caspase-3 activity were deter-
mined. Akt phosphorylation was significantly decreased, 
whereas caspase-3 activity was elevated in HUVECs sub-
jected to Akt inhibitor treatment compared to control 
(Fig.  6). These results strongly suggest Akt inhibition-
induced endothelial cell apoptosis contributes to reduced 
NO bioactivity in T-cad KO aortic tissue.
Increased nitric oxide inactivation exacerbated endothelial 
dysfunction in T‑cad KO mice
We next determined whether the endothelial dysfunc-
tion observed in T-cad deficient animals is related to 
increased superoxide production and nitric oxide inac-
tivation. Tissue nitrotyrosine level was determined, the 
accepted in vivo footprint of peroxynitrite (ONOO−), the 
10-7 10-6 10-5 10-4
Ach(M)
**
10-7 10-6 10-5 10-4
Ach(M)
WT HGHF T-cad KO
HGHF
T-cad KO
HFD 8w
a b
**
WT HFD 8w
**
**
Fig. 3 T-cad deficiency induced-endothelial dysfunction was exacerbated in T2DM. Concentration-dependent vasorelaxation of aortic vascular 
rings subjected to a high glucose/high fat treatment (high glucose: 25.5 m mol/l; high fat/palmitate: 300 μ mol/l) and b high fat diet alone for 
8 weeks. Top representative figures; Bottom analysis result. Each mouse aorta generated 2–3 rings, n = 6–7 rings/group. WT Wild type litternates, 
T-cad KO T-cadherin knockout mice. **P < 0.01 vs. WT
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product of NO and superoxide. Superoxide production 
was markedly increased in T-cad KO animals, and nitro-
tyrosine was significantly increased in T-cad KO mice 
compared to WT (Fig.  7). These results support aug-
mented NO inactivation as a primary cause of endothe-
lial dysfunction in T-cad deficient animals.
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Fig. 4 Basal NO production was significantly decreased in vascular segments from T-cad deficient animals. a NO concentration in culture medium 
after 8 h incubation of aortic segments from WT or T-cadherin knockout mice. b Concentration of nitric oxide in medium after Ach stimulation. Each 
mouse aorta generated 2 aortic segments. n = 8 segments/group. *P < 0.05 vs. WT
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Fig. 5 Phosphorylation of Akt, but not eNOS, was significantly reduced in aortic tissue from T-cad KO animals. Expression of Akt, p-Akt, eNOS and 
p-eNOS in aortic tissues obtained from WT or T-cadherin knockout mice. Left representative Western blots. Right summary of density analysis of 
p-Akt/Akt (a) and p-eNOS/eNOS (b), n = 3 mice/group, *P < 0.05 vs. WT
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Discussion
Adiponectin (APN) is a multifunctional adipocytokine 
of adipose tissue origin. APN exists in three isoforms 
(trimer, hexamer, and multimer). Plasma APN concen-
tration (which consists of mostly the latter two high 
molecular weight isoforms) highly correlates with the 
development of T2DM. Numerous studies have shown 
that plasma adiponectin level is decreased in individu-
als with T2DM, indicating APN plays an important 
role in pathogenesis of T2DM [18–20]. T-cad has been 
identified as an important receptor of APN, particularly 
for the high molecular weight isoform [21–24]. Both 
plasma APN concentration and tissue APN expression 
are closely related with T-cad [14]. Additionally, T-cad 
itself is implicated with the pathogenesis of T2DM, but 
with uncertain role [25, 26]. In the present study, we have 
provided the first in vivo evidence that T-cad expression 
is decreased in the aorta from T2DM animals (Fig.  1). 
This data is consistent with Matsuda’s study demonstrat-
ing T-cad expression is positively correlated with plasma 
APN concentration, which is markedly decreased in 
T2DM patients [14].
Atherosclerosis is the basis for the vascular pathologies 
of T2DM. Endothelial dysfunction plays a key role in this 
process, and the ongoing underlying mechanisms [27–
29]. Many studies have demonstrated T-cad plays a cen-
tral multifunctional role in the vascular system [30–34]. 
Heretofore, no direct in  vivo functional evidence exists 
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Fig. 6 Akt inactivation increased caspase-3 activity in HUVECs. a Representative Western blots of p-Akt and Akt expression in HUVECs with or with-
out Akt inhibitor; b Caspase-3 activity, using Ac-DEVD-pNA as substrate, n = 3, *P < 0.05 vs. WT
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Fig. 7 Increased nitric oxide inactivation exacerbated endothelial dysfunction in T-cad KO mice. a Aortic nitrotyrosine content determined by 
ELISA; b quantitative assay of superoxide production determined by lucigenin-enhanced chemiluminescence, n = 3–4 mice/group, *P < 0.05 vs. 
WT, **P < 0.01 vs. WT
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demonstrating the role T-cad plays in endothelial dys-
function. We next performed a vascular ring experiment 
to study the relationship between T-cad and endothe-
lial dysfunction. Our results demonstrated significantly 
reduced vasorelaxation in T-cad KO mice compared to 
WT, consistent with numerous in  vitro studies (Fig.  2) 
[35, 36], suggesting T-cad deficiency may cause severe 
endothelial dysfunction. To investigate whether T2DM 
exacerbates endothelial dysfunction already caused by 
T-cad deficiency, we fed mice high-fat diet for 8 weeks to 
mimic T2DM. Our resultant data provide the first in vivo 
functional evidence T-cad deficiency exacerbates severe 
endothelial dysfunction in the T2DM condition (Fig. 3).
NO, produced by eNOS, is a critical vasodilator in the 
vascular system. NO bioavailability is a surrogate marker 
of endothelial cell function. To obtain further evidence 
supporting endothelial dysfunction occurs in T-cad KO 
vascular segments, we next performed total NO accumu-
lation and NOx production. Our results confirmed that 
NO production and NOx production were both reduced 
in T-cad deficient animals (Fig. 4), suggesting T-cad defi-
ciency was associated with reduced NO production, 
which may be responsible in part for the observed state 
of endothelial dysfunction.
Interestingly, phosphorylation of Akt was significantly 
decreased in T-cad KO animals, while phosphorylation of 
eNOS was grossly unchanged compared to WT (Fig. 5). 
At the beginning, we thought this reduction in Akt phos-
phorylation may induce the reduction in eNOS phos-
phorylation, which is a classical factor to mediate NO 
production [37]. But our eNOS results, which are consist-
ent with the data of others, did not support this hypothesis 
[9]. The PI3 k/Akt pathway is highly associated with apop-
tosis [38]. The reduction in Akt phosphorylation may be 
contributive to apoptosis induction in EC, which partially 
explains why NO and NOx production were reduced in 
EC in vascular segments in T-cad KO mice. Therefore, we 
utilized Akt inhibitor to attenuate Akt phosphorylation 
and found caspase-3 activity was significantly increased in 
HUVECs subjected to Akt inhibitor (Fig. 6). Collectively, 
our results, which is consistent with the data of others [9, 
35], suggested Akt inhibition induced apoptosis, but not 
reduced eNOS phosphorylation, contributes to decreased 
NOx production in ECs. Further studies directly address-
ing this phenomenon are expected.
Experimental and clinical data have demonstrated aug-
mented superoxide production and the resultant super-
oxide/nitric oxide bi-radical reaction is the primary 
cause for NO inactivation under pathological conditions. 
Newly produced NO is oxidized to NO2− and NO3− rap-
idly under physiological conditions, reducing NO bio-
availability and its vasorelaxative potential, termed NO 
inactivation. In the presence of superoxide, NO forms 
peroxynitrite (ONOO−), a toxic molecule that modi-
fies tyrosine residues in proteins to create nitrotyrosine, 
leaving a footprint detectable in vivo [39]. In our present 
study, we have demonstrated both increased superoxide 
and nitrotyrosine content in T-cad KO animals (Fig. 7).
Conclusions
We have provided the first in  vivo evidence that T-cad 
deficiency causes endothelial dysfunction in T2DM 
model vascular segments, supporting T-cad deficiency 
involvement in the pathogenesis of T2DM complications. 
Supplanting T-cad deficiency may be a potential thera-
peutic avenue in the prevention and amelioration of vas-
cular injury in the diabetic population.
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